Femasys Expands Fertility Access via CapexMD Financing Partnership
Event summary
- Femasys partners with CapexMD to offer financing for its FemaSeed fertility portfolio, including diagnostics and in-office treatments.
- The collaboration aims to reduce financial barriers for patients seeking first-line fertility care, such as FemaSeed Complete.
- CapexMD will provide dedicated financing solutions for Femasys’ offerings across OB/GYN practices and fertility centers.
- Femasys’ portfolio includes FemVue and SpermVue diagnostics, alongside FemaSeed for intratubal insemination.
The big picture
Femasys’ partnership with CapexMD aligns with the broader trend of expanding access to affordable fertility care, particularly as patients seek earlier, less invasive treatment options. The collaboration underscores the growing importance of financing solutions in reducing barriers to care, a critical factor in the competitive fertility market. Femasys’ focus on integrating diagnostics and treatment into OB/GYN settings positions it to capture a larger share of the fertility care pathway.
What we're watching
- Market Expansion
- How Femasys will leverage CapexMD’s financing to accelerate adoption of FemaSeed in OB/GYN and fertility practices.
- Regulatory Progress
- The pace at which Femasys advances FemBloc toward U.S. FDA approval, following its international regulatory approvals.
- Competitive Positioning
- Whether Femasys can sustain differentiation with its lower-cost fertility solutions amid increasing industry competition.
Related topics